MEP3108A - Kompozicije i postupci za povećanje mineralizacije kostiju - Google Patents

Kompozicije i postupci za povećanje mineralizacije kostiju

Info

Publication number: MEP3108A
Authority: ME; Montenegro
Prior art keywords: methods; tgf; compositions; bone; mineral density
Prior art date: 2003-06-16

Application number

MEP-31/08A

Other languages

Bosnian (bs)

English (en)

Inventor

Mary Brunkow

David Galas

Brian Kovacevich

John Mulligan

Bryan Paeper

Ness Jeffrey Van

David Winkler

Original Assignee

Celltech R & D Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-16

Filing date

2004-06-15

Publication date

2010-02-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33563705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP3108(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-06-15 Application filed by Celltech R & D Inc filed Critical Celltech R & D Inc

2010-02-10 Publication of MEP3108A publication Critical patent/MEP3108A/xx

Links

238000000034 method Methods 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 3
230000018678 bone mineralization Effects 0.000 title abstract 2
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 4
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 4
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 4
102000023732 binding proteins Human genes 0.000 abstract 3
108091008324 binding proteins Proteins 0.000 abstract 3
210000000988 bone and bone Anatomy 0.000 abstract 3
208000029725 Metabolic bone disease Diseases 0.000 abstract 2
229910052500 inorganic mineral Inorganic materials 0.000 abstract 2
239000011707 mineral Substances 0.000 abstract 2
208000010392 Bone Fractures Diseases 0.000 abstract 1
206010049088 Osteopenia Diseases 0.000 abstract 1
208000001164 Osteoporotic Fractures Diseases 0.000 abstract 1
102000019307 Sclerostin Human genes 0.000 abstract 1
108050006698 Sclerostin Proteins 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000003993 interaction Effects 0.000 abstract 1
230000002452 interceptive effect Effects 0.000 abstract 1
230000000921 morphogenic effect Effects 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Rheumatology (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)

MEP-31/08A 2003-06-16 2004-06-15 Kompozicije i postupci za povećanje mineralizacije kostiju MEP3108A (xx)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10/463,190 US20040009535A1 (en)	1998-11-27	2003-06-16	Compositions and methods for increasing bone mineralization
PCT/US2004/018910 WO2005003158A2 (en)	2003-06-16	2004-06-15	Compositions and methods for increasing bone mineralization
YU20050932A RS52769B (sr)	2003-06-16	2004-06-15	Kompozicije i postupci za povećanje mineralizacije kostiju

Publications (1)

Publication Number	Publication Date
MEP3108A true MEP3108A (xx)	2010-02-10

Family

ID=33563705

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MEP-31/08A MEP3108A (xx)	2003-06-16	2004-06-15	Kompozicije i postupci za povećanje mineralizacije kostiju
MEP-2008-31A ME00023B (me)	2003-06-16	2004-06-15	Kompozicije i postupci za povećanje mineralizacije kostiju

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MEP-2008-31A ME00023B (me)	2003-06-16	2004-06-15	Kompozicije i postupci za povećanje mineralizacije kostiju

Country Status (24)

Country	Link
US (3)	US20040009535A1 (xx)
EP (3)	EP2341071A1 (xx)
JP (2)	JP4818107B2 (xx)
KR (1)	KR101221147B1 (xx)
CN (2)	CN103319596A (xx)
AU (1)	AU2004253870B2 (xx)
BR (1)	BRPI0411535A (xx)
CA (1)	CA2529578C (xx)
CY (1)	CY1114701T1 (xx)
DK (1)	DK1638999T3 (xx)
EA (2)	EA022991B1 (xx)
ES (1)	ES2428767T3 (xx)
HR (1)	HRP20131014T1 (xx)
IL (2)	IL172599A (xx)
ME (2)	MEP3108A (xx)
NO (1)	NO20060235L (xx)
NZ (1)	NZ544617A (xx)
PL (1)	PL1638999T3 (xx)
PT (1)	PT1638999E (xx)
RS (1)	RS52769B (xx)
SG (1)	SG185824A1 (xx)
SI (1)	SI1638999T1 (xx)
WO (1)	WO2005003158A2 (xx)
ZA (1)	ZA200600384B (xx)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2352532C (en)	1998-11-27	2014-10-14	Darwin Discovery Ltd.	Compositions and methods for increasing bone mineralization
US20040009535A1 (en)	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
JP4662714B2 (ja) *	2002-03-01	2011-03-30	セルテックアールアンドディーインコーポレイテッド	骨密度を増減させる方法
US7193069B2 (en)	2002-03-22	2007-03-20	Research Association For Biotechnology	Full-length cDNA
AU2003221841A1 (en)	2002-04-03	2003-10-27	Celltech R And D, Inc.	Association of polymorphisms in the sost gene region with bone mineral density
US7893218B2 (en)	2003-06-16	2011-02-22	Stowers Institute For Medical Research	Antibodies that specifically bind SOST peptides
US7585501B2 (en)	2002-06-14	2009-09-08	Stowers Institute For Medical Research	Compositions and methods for treating kidney disease
WO2003106657A2 (en)	2002-06-14	2003-12-24	Stowers Institute For Medical Research	Wise/sost nucleic acid sequences and amino acid sequences
NZ544618A (en)	2003-06-16	2009-02-28	Celltech R & D Inc	Antibodies specific for sclerostin and methods for increasing bone mineralization
US9046537B2 (en)	2003-09-22	2015-06-02	Enzo Biochem, Inc.	Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US8461155B2 (en) *	2003-09-22	2013-06-11	University Of Connecticut	Sclerostin and the inhibition of WNT signaling and bone formation
US8637506B2 (en) *	2003-09-22	2014-01-28	Enzo Biochem, Inc.	Compositions and methods for bone formation and remodeling
US20100041599A1 (en) *	2006-11-14	2010-02-18	Dakai Liu	Compositions and methods for bone formation, bone remodeling and toxin protection
US8367822B2 (en) *	2003-09-22	2013-02-05	Enzo Therapeutics, Inc.	Compositions and methods for bone formation and remodeling
US9052324B2 (en)	2004-05-19	2015-06-09	Enzo Biochem, Inc.	Compounds and assays for controlling Wnt activity
US8343922B2 (en) *	2004-05-19	2013-01-01	Enzo Biochem, Inc.	Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
CA2567810A1 (en)	2004-05-27	2005-12-08	Acceleron Pharma Inc.	Cerberus/coco derivatives and uses thereof
US9045553B2 (en)	2004-05-27	2015-06-02	Acceleron Pharma, Inc.	Cerberus/Coco derivatives and uses thereof
CA2574777C (en)	2004-07-23	2015-09-01	Acceleron Pharma Inc.	Actrii receptor polypeptides, methods and compositions
ITMI20050739A1 (it) *	2005-04-22	2006-10-23	Effebi Spa	Piastrina di connsessione valvola-attuatore
US7592429B2 (en) *	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
US8003108B2 (en) *	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
US8263137B2 (en) *	2005-08-04	2012-09-11	Vertical Pharmaceuticals, Inc.	Nutritional supplement for women
US7901710B2 (en) *	2005-08-04	2011-03-08	Vertical Pharmaceuticals, Inc.	Nutritional supplement for use under physiologically stressful conditions
US8202546B2 (en)	2005-08-04	2012-06-19	Vertical Pharmaceuticals, Inc.	Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) *	2005-08-04	2011-08-16	Vertical Pharmaceuticals, Inc.	Nutritional supplement for women
EP1973559B1 (en) *	2005-11-23	2013-01-09	Acceleron Pharma Inc.	Activin-actriia antagonists and uses for promoting bone growth
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
US20090203041A1 (en) *	2006-04-21	2009-08-13	Wei Shi	Bmp4 inhibitors
WO2008133722A2 (en) *	2006-11-10	2008-11-06	Ucb Pharma S.A.	Anti human sclerostin antibodies
EP2097450A2 (en) *	2006-11-10	2009-09-09	Amgen Inc.	Antibody-based diagnostics and therapeutics
EP2099471A2 (en)	2006-12-08	2009-09-16	Acceleron Pharma, Inc.	Uses of cerberus, coco and derivatives thereof
US8895016B2 (en)	2006-12-18	2014-11-25	Acceleron Pharma, Inc.	Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2009131553A2 (en) *	2006-12-29	2009-10-29	Osteogenex Inc.	Methods of altering bone growth by administration of sost or wise antagonist or agonist
RU2473362C2 (ru)	2007-02-01	2013-01-27	Акселерон Фарма Инк.	АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
TW202021980A (zh)	2007-02-02	2020-06-16	美商艾瑟勒朗法瑪公司	衍生自ActRIIB的變體與其用途
KR20180083967A (ko)	2007-02-09	2018-07-23	악셀레론 파마 인코포레이티드	액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
EA018204B1 (ru)	2007-03-20	2013-06-28	Эли Лилли Энд Компани	Антитела против склеростина
US8133553B2 (en)	2007-06-18	2012-03-13	Zimmer, Inc.	Process for forming a ceramic layer
US8309521B2 (en)	2007-06-19	2012-11-13	Zimmer, Inc.	Spacer with a coating thereon for use with an implant device
CL2008002775A1 (es)	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CN107412734A (zh)	2007-09-18	2017-12-01	阿塞勒隆制药公司	活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
US8608049B2 (en)	2007-10-10	2013-12-17	Zimmer, Inc.	Method for bonding a tantalum structure to a cobalt-alloy substrate
TWI489993B (zh)	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
JP2011506483A (ja) *	2007-12-14	2011-03-03	アムジエン・インコーポレーテツド	抗スクレロスチン抗体を用いた骨折の治療方法
JPWO2009110215A1 (ja) *	2008-03-03	2011-07-14	独立行政法人科学技術振興機構	繊毛細胞の分化誘導方法
US8198292B2 (en) *	2008-07-03	2012-06-12	Osteogenex, Inc.	Vinpocetine and eburnamonine derivatives for promoting bone growth, treating renal damage and cancer, and devices thereof
US8216997B2 (en)	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
ES2949049T3 (es)	2008-08-14	2023-09-25	Acceleron Pharma Inc	Trampas de GDF
WO2010083034A1 (en)	2009-01-13	2010-07-22	Acceleron Pharma Inc.	Methods for increasing adiponectin
AU2010211438B2 (en) *	2009-02-06	2016-04-14	Academisch Ziekenhuis Maastricht	Truncated cystine-knot proteins
US8338377B2 (en)	2009-03-30	2012-12-25	Acceleron Pharma Inc.	BMP-ALK3 antagonists and uses for promoting bone growth
WO2010115932A1 (en)	2009-04-08	2010-10-14	Novartis Ag	Combination for the treatment of bone loss
WO2010130830A2 (en) *	2009-05-15	2010-11-18	Ablynx N.V.	Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
CN102482339B (zh)	2009-06-08	2015-06-17	阿塞勒隆制药公司	用于增加产热脂肪细胞的方法
KR20210034684A (ko)	2009-06-12	2021-03-30	악셀레론 파마 인코포레이티드	절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
AU2010322011B2 (en)	2009-11-17	2016-03-31	Acceleron Pharma Inc.	ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US20130138221A1 (en)	2010-04-16	2013-05-30	Novartis Ag	Methods and compositions for improving implant osseointegration
SMT202000095T1 (it)	2010-05-14	2020-03-13	Amgen Inc	Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
US9403882B2 (en)	2010-06-07	2016-08-02	Joshua Rabbani	Sulfation of Wnt pathway proteins
US9493541B2 (en)	2010-06-07	2016-11-15	Joshua Rabbani	Antibodies specific for sulfated sclerostin
US11167011B2 (en)	2010-06-07	2021-11-09	Enzo Biochem, Inc.	Methods for treating bone loss using sclerostin peptides
US9617323B2 (en)	2010-06-07	2017-04-11	Joshua Rabbani	Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
PT3111954T (pt)	2010-11-05	2019-07-10	Novartis Ag	Métodos de tratamento da espondilite anquilosante usando anticorpos anti-il-17
CN103298832A (zh)	2010-11-08	2013-09-11	阿塞勒隆制药公司	Actriia结合剂及其用途
CN103649118A (zh)	2011-03-01	2014-03-19	安进公司	双特异性结合剂
SG193610A1 (en)	2011-03-25	2013-11-29	Amgen Inc	Anti - sclerostin antibody crystals and formulations thereof
FR2974061B1 (fr)	2011-04-13	2013-06-07	Michelin Soc Tech	Procede et dispositif de comptage du nombre d'atterrissages d'un pneumatique d'un aeronef
US20140127192A1 (en)	2011-04-19	2014-05-08	Amgen Inc	Method for treating osteoporosis
EP2702408A1 (en)	2011-04-29	2014-03-05	Novartis AG	Methods of treating squamous cell carcinoma related applications
EP2734540B1 (en) *	2011-07-19	2017-11-22	University Health Network	Biomarkers for ankylosing spondylitis
ES2667554T3 (es)	2011-08-04	2018-05-11	Amgen Inc.	Método para el tratamiento de los defectos de espacio óseo
DK3453711T3 (da)	2011-09-02	2021-10-18	Univ California	Llp2a-bisphosphonatkonjugater til behandling mod osteoporose
MX354270B (es)	2011-12-28	2018-02-21	Amgen Inc	Uso de un anticuerpo antiesclerostina en el tratamiento de la pérdida ósea alveolar. .
EP2869844B2 (en)	2012-07-05	2023-06-21	UCB Pharma S.A.	Treatment for bone diseases
RU2678117C2 (ru)	2012-11-02	2019-01-23	Селджин Корпорейшн	Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
WO2014118705A1 (en)	2013-01-31	2014-08-07	Novartis Ag	Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
US9708375B2 (en)	2013-03-15	2017-07-18	Amgen Inc.	Inhibitory polypeptides specific to WNT inhibitors
SI2976359T2 (sl)	2013-03-20	2022-05-31	Genzyme Corporation	Postopki zdravljenja imperfektne osteogeneze
WO2014155278A2 (en)	2013-03-26	2014-10-02	Novartis Ag	Methods of treating autoimmune diseases using il-17 antagonists
CN110639024A (zh)	2013-05-03	2020-01-03	西莱克塔生物科技公司	用于增强cd4+调节性t细胞的方法和组合物
BR112016029226A2 (pt)	2014-06-13	2017-10-17	Acceleron Pharma Inc	métodos e composições para o tratamento de úlceras
MA41052A (fr)	2014-10-09	2017-08-15	Celgene Corp	Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
TWI773117B (zh)	2014-12-03	2022-08-01	美商西建公司	活化素-actrii拮抗劑及治療貧血之用途
MA41142A (fr)	2014-12-12	2017-10-17	Amgen Inc	Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
GB201510758D0 (en)	2015-06-18	2015-08-05	Ucb Biopharma Sprl	Novel TNFa structure for use in therapy
GB201604124D0 (en)	2016-03-10	2016-04-27	Ucb Biopharma Sprl	Pharmaceutical formulation
KR20190037261A (ko)	2016-08-08	2019-04-05	암젠 인크	항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법
CN110325548B (zh)	2016-12-21	2023-11-17	美莱奥生物制药第三有限公司	抗硬化蛋白抗体在治疗成骨不全症中的用途
JP2020502218A (ja)	2016-12-21	2020-01-23	メレオバイオファーマ３リミテッド	骨形成不全症の処置における抗スクレロスチン抗体の使用
GB201621907D0 (en) *	2016-12-21	2017-02-01	Ucb Biopharma Sprl And Sanofi	Antibody epitope
RU2651091C1 (ru) *	2016-12-22	2018-04-18	Федеральное Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПбГПМУ Минздрава России)	Способ диагностики остеомиелита у детей
MX2019010757A (es)	2017-03-11	2020-01-20	Selecta Biosciences Inc	Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
CN111712573B (zh) *	2018-02-12	2023-10-20	安沛治疗有限公司	针对骨硬化蛋白的适体及其用途
JP7405764B2 (ja)	2018-03-30	2023-12-26	アムジエン・インコーポレーテツド	Ｃ末端抗体改変体
GB201810746D0 (en)	2018-06-29	2018-08-15	Mereo Biopharma 3 Ltd	Use of sclerostin antagonist
EP3833327A1 (en)	2018-08-10	2021-06-16	Amgen Inc.	Method of preparing an antibody pharmaceutical formulation
CN114630677A (zh)	2019-08-12	2022-06-14	安进公司	抗硬骨素抗体配制品
TW202510908A (zh)	2023-07-19	2025-03-16	美商安進公司	用於治療性蛋白質配製物的緩衝液製備方法
CN121293275A (zh) *	2025-12-12	2026-01-09	湖南师范大学	一种具有抗氧化活性的多肽及其应用

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US751929A (en)		1904-02-09		Ash-pan
US793398A (en)	1905-03-24	1905-06-27	Herschel A Schermerhorn	Fastening for wagon eng-gates.
US4018884A (en)	1975-06-26	1977-04-19	Hoffmann-La Roche Inc.	Fluorogenic materials and labeling techniques
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
US4359535A (en)	1979-10-01	1982-11-16	George Pieczenik	Autonomously replicating DNA containing inserted DNA sequences
US4528266A (en)	1979-10-01	1985-07-09	George Pieczenik	Method of inserting unique DNA sequences into DNA vectors
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4331647A (en)	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4486530A (en)	1980-08-04	1984-12-04	Hybritech Incorporated	Immunometric assays using monoclonal antibodies
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4411993A (en)	1981-04-29	1983-10-25	Steven Gillis	Hybridoma antibody which inhibits interleukin 2 activity
US4873191A (en)	1981-06-12	1989-10-10	Ohio University	Genetic transformation of zygotes
US4427115A (en)	1981-10-19	1984-01-24	Laipply Thomas C	One piece alcohol preparation device
US4579821A (en)	1981-11-23	1986-04-01	University Patents, Inc.	Control of DNA sequence transcription
USRE32011E (en)	1981-12-14	1985-10-22	Scripps Clinic And Research Foundation	Ultrapurification of factor VIII using monoclonal antibodies
JPS58117537A (ja)	1982-01-06	1983-07-13	Toray Ind Inc	感光性樹脂組成物
US4766075A (en)	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
US4543439A (en)	1982-12-13	1985-09-24	Massachusetts Institute Of Technology	Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US6054561A (en)	1984-02-08	2000-04-25	Chiron Corporation	Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de)	1984-05-11	1986-01-09	Matter + Siegmann Ag, Wohlen	Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US5288641A (en)	1984-06-04	1994-02-22	Arch Development Corporation	Herpes Simplex virus as a vector
US5087571A (en)	1984-06-22	1992-02-11	President And Fellows Of Harvard College	Method for providing a cell culture from a transgenic non-human mammal
US4736866B1 (en)	1984-06-22	1988-04-12		Transgenic non-human mammals
DE3583940D1 (de)	1984-10-02	1991-10-02	Harry M Meade	Herstellung von streptavidinaehnlichen polypeptiden.
US5272254A (en)	1984-10-02	1993-12-21	Biogen Inc.	Production of streptavidin-like polypeptides
US4801542A (en)	1984-10-12	1989-01-31	Zymogenetics, Inc.	Expression of biologically active PDGF analogs in eucaryotic cells
SG64329A1 (en)	1984-11-16	1999-04-27	American Cyanamid Co	Antitumor antibiotics (LL-E33288 complex)
US4902614A (en)	1984-12-03	1990-02-20	Teijin Limited	Monoclonal antibody to human protein C
US4897255A (en)	1985-01-14	1990-01-30	Neorx Corporation	Metal radionuclide labeled proteins for diagnosis and therapy
US5506337A (en)	1985-03-15	1996-04-09	Antivirals Inc.	Morpholino-subunit combinatorial library and method
GR860984B (en)	1985-04-17	1986-08-18	Zymogenetics Inc	Expression of factor vii and ix activities in mammalian cells
CA1293460C (en)	1985-10-07	1991-12-24	Brian Lee Sauer	Site-specific recombination of dna in yeast
US4744981A (en)	1985-10-17	1988-05-17	Neorx Corporation	Trichothecene antibody conjugates
US4935349A (en)	1986-01-17	1990-06-19	Zymogenetics, Inc.	Expression of higher eucaryotic genes in aspergillus
US5811128A (en)	1986-10-24	1998-09-22	Southern Research Institute	Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en)	1986-10-24	1991-12-24	Southern Research Institute	Method of potentiating an immune response
US4987071A (en)	1986-12-03	1991-01-22	University Patents, Inc.	RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4851341A (en)	1986-12-19	1989-07-25	Immunex Corporation	Immunoaffinity purification system
US5079233A (en)	1987-01-30	1992-01-07	American Cyanamid Company	N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5219740A (en)	1987-02-13	1993-06-15	Fred Hutchinson Cancer Research Center	Retroviral gene transfer into diploid fibroblasts for gene therapy
EP0289121B1 (en)	1987-05-01	1995-12-27	Stratagene	Mutagenesis testing using transgenic non-human animals carrying test DNA sequences
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
JPH02500329A (ja)	1987-05-21	1990-02-08	クリエイテイブ・バイオマリキユールズ・インコーポレーテツド	ターゲット化多機能蛋白質
US5132405A (en)	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US4897268A (en)	1987-08-03	1990-01-30	Southern Research Institute	Drug delivery system and method of making the same
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
GB8723661D0 (en)	1987-10-08	1987-11-11	British Bio Technology	Synthetic gene
US5202238A (en)	1987-10-27	1993-04-13	Oncogen	Production of chimeric antibodies by homologous recombination
DE3851682T2 (de)	1987-10-30	1995-05-04	American Cyanamid Co	Targetformer von Antitumor-Methyltrithioagenzien.
US5254678A (en)	1987-12-15	1993-10-19	Gene Shears Pty. Limited	Ribozymes
EP0329184A3 (en)	1988-02-19	1990-05-23	Neorx Corporation	Antimers and antimeric conjugation
US4988496A (en)	1988-05-31	1991-01-29	Neorx Corporation	Metal radionuclide chelating compounds for improved chelation kinetics
US5221778A (en)	1988-08-24	1993-06-22	Yale University	Multiplex gene regulation
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
DE68927933T2 (de)	1988-09-02	1997-08-14	Dyax Corp	Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
CA1340323C (en)	1988-09-20	1999-01-19	Arnold E. Hampel	Rna catalyst for cleaving specific rna sequences
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5096815A (en)	1989-01-06	1992-03-17	Protein Engineering Corporation	Generation and selection of novel dna-binding proteins and polypeptides
WO1990007936A1 (en)	1989-01-23	1990-07-26	Chiron Corporation	Recombinant therapies for infection and hyperproliferative disorders
GB8903022D0 (en)	1989-02-10	1989-03-30	Celltech Ltd	Chemical compounds
US5175383A (en)	1989-02-17	1992-12-29	President And Fellows Of Harvard College	Animal model for benign prostatic disease
US5549910A (en)	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
DE69024953T3 (de)	1989-05-04	2005-01-27	Southern Research Institute, Birmingham	Einkapselungsverfahren
GB8914543D0 (en)	1989-06-23	1989-08-09	Parker David	Chemical compounds
EP0845537A1 (en)	1989-08-18	1998-06-03	Chiron Corporation	Recombinant retroviruses delivering vector constructs to target cells
US5464764A (en)	1989-08-22	1995-11-07	University Of Utah Research Foundation	Positive-negative selection methods and vectors
KR920007887B1 (ko)	1989-08-29	1992-09-18	스즈키 지도오샤 고오교오 가부시키가이샤	내연기관의 배기가스 정화장치
GB8919607D0 (en)	1989-08-30	1989-10-11	Wellcome Found	Novel entities for cancer therapy
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5359051A (en)	1990-01-11	1994-10-25	Isis Pharmaceuticals	Compounds useful in the synthesis of nucleic acids capable of cleaning RNA
EP0438803B1 (en)	1990-01-26	1997-03-12	Immunomedics, Inc.	Vaccines against cancer and infectious diseases
US5177197A (en)	1990-02-27	1993-01-05	Ludwig Institute For Cancer Research	Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en)	1990-04-03	1995-11-14	Ciba-Geigy Corporation	Parenterally administrable liposome formulation comprising synthetic lipids
JPH06507782A (ja)	1990-06-15	1994-09-08	サイオス　ノバ　インコーポレイテッド	アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
JP3218637B2 (ja)	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
WO1992002551A1 (en)	1990-08-02	1992-02-20	B.R. Centre Limited	Methods for the production of proteins with a desired function
JP2958076B2 (ja)	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
JPH04141095A (ja)	1990-10-02	1992-05-14	Chemo Sero Therapeut Res Inst	組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en)	1990-10-12	1991-12-03	Trustees Of The University Of Pennsylvania	Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
EP0554376A4 (en)	1990-10-22	1994-08-24	Fox Chase Cancer Center	Dna construct for providing rna therapy
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5399363A (en)	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
ATE363532T1 (de)	1991-03-01	2007-06-15	Dyax Corp	Verfahren zur herstellung bindender miniproteine
US6072039A (en)	1991-04-19	2000-06-06	Rohm And Haas Company	Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
DE4135543A1 (de)	1991-10-28	1993-04-29	Boehringer Mannheim Gmbh	Rekombinantes core-streptavidin
US5203975A (en)	1991-10-29	1993-04-20	E. I. Du Pont De Nemours And Company	Process for cathodic electrodeposition of a clear coating over a conductive paint layer
WO1993010218A1 (en)	1991-11-14	1993-05-27	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Vectors including foreign genes and negative selective markers
GB9125623D0 (en)	1991-12-02	1992-01-29	Dynal As	Cell modification
DE69309472T2 (de)	1992-01-23	1997-10-23	Merck Patent Gmbh, 64293 Darmstadt	Fusionsproteine von monomeren und dimeren von antikörperfragmenten
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
EP0578515A3 (en)	1992-05-26	1995-05-10	Bristol Myers Squibb Co	Humanized monoclonal antibodies.
WO1993024631A1 (en)	1992-05-29	1993-12-09	E.I. Du Pont De Nemours And Company	PRODUCTION OF STREPTAVIDIN FROM $i(BACILLUS SUBTILIS)
EP0650370A4 (en)	1992-06-08	1995-11-22	Univ California	METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
WO1993025698A1 (en)	1992-06-10	1993-12-23	The United States Government As Represented By The	Vector particles resistant to inactivation by human serum
GB2269175A (en)	1992-07-31	1994-02-02	Imperial College	Retroviral vectors
US5288514A (en)	1992-09-14	1994-02-22	The Regents Of The University Of California	Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
DK0678034T3 (da)	1993-01-11	1999-11-08	Dana Farber Cancer Inst Inc	Induktion af cytotoksiske T-lymfocytreaktioner
IL108719A0 (en)	1993-02-25	1994-08-26	Ortho Pharma Corp	Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
FR2702160B1 (fr)	1993-03-02	1995-06-02	Biovecteurs As	Vecteurs particulaires synthétiques et procédé de préparation.
FR2704145B1 (fr)	1993-04-21	1995-07-21	Pasteur Institut	Vecteur particulaire et composition pharmaceutique le contenant.
FR2705361B1 (fr)	1993-05-18	1995-08-04	Centre Nat Rech Scient	Vecteurs viraux et utilisation en thérapie génique.
NZ267838A (en)	1993-06-07	1997-12-19	Genentech Inc	Preparation of an hiv gp 120 subunit vaccine involving determining a neutralising epitope in the v2 and/or c4 domains
JPH09506857A (ja)	1993-07-16	1997-07-08	オントーゲンコーポレーション	多成分組合せアレイ合成による有機化合物の組合せアレイの合成
US5543158A (en)	1993-07-23	1996-08-06	Massachusetts Institute Of Technology	Biodegradable injectable nanoparticles
US5453492A (en)	1993-07-28	1995-09-26	La Jolla Cancer Research Foundation	60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
AU7329394A (en)	1993-08-03	1995-02-28	Sphinx Pharmaceuticals Corporation	A method for preparing and selecting pharmaceutically useful non-peptide compounds from a structurally diverse universal library
US5624803A (en)	1993-10-14	1997-04-29	The Regents Of The University Of California	In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
ES2216005T3 (es)	1993-11-09	2004-10-16	Targeted Genetics Corporation	Produccion de titulos elevados de vectores de aav recombinantes.
CA2175078A1 (en)	1993-12-09	1995-06-15	Eduard Felder	Process for the production of combinatorial compound libraries
SG48166A1 (en)	1993-12-15	1998-04-17	Conbichem Inc	Combinatorial libraries and methods for their use
WO1995016712A1 (en)	1993-12-15	1995-06-22	Smithkline Beecham Corporation	Compounds and methods
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
ATE239680T1 (de)	1994-03-11	2003-05-15	Pharmacopeia Inc	Sulfonamid derivate und deren verwendung
JPH10511840A (ja)	1994-04-29	1998-11-17	クリエイティブバイオモレキュールズ，インコーポレイテッド	形態形成タンパク質特異細胞表面レセプターおよびその使用
JPH10500112A (ja)	1994-05-06	1998-01-06	ファーマコピーア，インコーポレイテッド	組合せジヒドロベンゾピランライブラリー
US5549974A (en)	1994-06-23	1996-08-27	Affymax Technologies Nv	Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5792456A (en)	1994-08-04	1998-08-11	Bristol-Myers Squibb Company	Mutant BR96 antibodies reactive with human carcinomas
FR2723849B1 (fr)	1994-08-31	1997-04-11	Biovector Therapeutics Sa	Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5463564A (en)	1994-09-16	1995-10-31	3-Dimensional Pharmaceuticals, Inc.	System and method of automatically generating chemical compounds with desired properties
US5846770A (en)	1994-11-22	1998-12-08	Genetics Institute, Inc.	DNA molecules encoding human chordin
US6057421A (en)	1994-11-30	2000-05-02	Immpheron, Inc.	Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en)	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en)	1995-04-04	1998-07-29	Elan Corp Plc	Controlled release biodegradable nanoparticles containing insulin
EP0871705A4 (en)	1995-06-05	2000-01-26	Human Genome Sciences Inc	CCN TYPE HUMAN GROWTH FACTOR
US5738868A (en)	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
US6207153B1 (en)	1996-05-22	2001-03-27	Viventia Biotech, Inc.	Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US5989912A (en)	1996-11-21	1999-11-23	Oligos Etc. Inc.	Three component chimeric antisense oligonucleotides
WO2000075317A2 (en)	1999-06-09	2000-12-14	Genentech, Inc.	Compositions and methods for the treatment of tumor
US6133426A (en)	1997-02-21	2000-10-17	Genentech, Inc.	Humanized anti-IL-8 monoclonal antibodies
US5989909A (en)	1997-09-26	1999-11-23	Millennium Biotherapeutics, Inc.	Huchordin and uses thereof
US6117911A (en)	1997-04-11	2000-09-12	Neorx Corporation	Compounds and therapies for the prevention of vascular and non-vascular pathologies
DE69839147T2 (de)	1997-06-12	2009-02-19	Novartis International Pharmaceutical Ltd.	Künstliche antikörperpolypeptide
US6075007A (en)	1997-07-17	2000-06-13	Regeneron Pharmaceuticals, Inc.	Modified noggin polypeptide and compositions
WO1999006554A2 (en)	1997-08-01	1999-02-11	Genset	5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES
US6815201B2 (en)	1997-09-08	2004-11-09	The Public Health Research Institute Of The City Of New York, Inc.	HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
KR100581991B1 (ko)	1998-02-12	2006-05-23	이뮨 컴플렉스, 코포레이션	변형된 ｂ형 간염 코어 단백질 및 이의 유도체
US6544485B1 (en)	2001-01-29	2003-04-08	Sharper Image Corporation	Electro-kinetic device with enhanced anti-microorganism capability
US20040009535A1 (en)	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
CA2352532C (en)	1998-11-27	2014-10-14	Darwin Discovery Ltd.	Compositions and methods for increasing bone mineralization
AU2753100A (en)	1999-02-03	2000-08-25	Biosante Pharmaceuticals, Inc.	Therapeutic calcium phosphate particles and methods of manufacture and use
JP4141095B2 (ja)	1999-10-29	2008-08-27	三洋電機株式会社	半導体装置とその製造方法
JP2003525611A (ja)	2000-03-02	2003-09-02	アムジェンインコーポレーテッド	コルディン様−２分子およびその使用
CA2410912A1 (en) *	2000-06-01	2001-12-06	Amgen, Inc.	Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
JP2004520005A (ja)	2000-06-19	2004-07-08	エフ．ホフマン−ラ　ロシュ　アーゲー	オステオレビン遺伝子多型性
CA2421056A1 (en)	2000-09-01	2002-03-28	Genentech, Inc.	A polypeptide for use as a diagnostic marker for the presence of colon tumours
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en)	2001-03-13	2002-09-13	The Minister Of National Defence	Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
US20030186915A1 (en)	2002-02-11	2003-10-02	Yang Pan	Regulatory polynucleotides and uses thereof
FR2838379B1 (fr)	2002-04-12	2005-06-24	Valeo Climatisation	Dispositif de purification de l'air de l'habitacle d'un vehicule automobile
US7893218B2 (en)	2003-06-16	2011-02-22	Stowers Institute For Medical Research	Antibodies that specifically bind SOST peptides
WO2003106657A2 (en) *	2002-06-14	2003-12-24	Stowers Institute For Medical Research	Wise/sost nucleic acid sequences and amino acid sequences
DE10255152A1 (de)	2002-11-26	2004-06-03	Von Langen Ursula Lang	Schadstoffsauger
US20040141875A1 (en)	2003-01-15	2004-07-22	Rajiv Doshi	System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
NZ544618A (en) *	2003-06-16	2009-02-28	Celltech R & D Inc	Antibodies specific for sclerostin and methods for increasing bone mineralization
US7592429B2 (en) *	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
EA018204B1 (ru) *	2007-03-20	2013-06-28	Эли Лилли Энд Компани	Антитела против склеростина
TWI489993B (zh) *	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法

2003
- 2003-06-16 US US10/463,190 patent/US20040009535A1/en not_active Abandoned
2004
- 2004-06-15 AU AU2004253870A patent/AU2004253870B2/en active Active
- 2004-06-15 HR HRP20131014TT patent/HRP20131014T1/hr unknown
- 2004-06-15 PT PT47765524T patent/PT1638999E/pt unknown
- 2004-06-15 CA CA2529578A patent/CA2529578C/en not_active Expired - Lifetime
- 2004-06-15 NZ NZ544617A patent/NZ544617A/en not_active IP Right Cessation
- 2004-06-15 DK DK04776552.4T patent/DK1638999T3/da active
- 2004-06-15 EA EA201001528A patent/EA022991B1/ru not_active IP Right Cessation
- 2004-06-15 SI SI200432101T patent/SI1638999T1/sl unknown
- 2004-06-15 ES ES04776552T patent/ES2428767T3/es not_active Expired - Lifetime
- 2004-06-15 JP JP2006517259A patent/JP4818107B2/ja not_active Expired - Lifetime
- 2004-06-15 CN CN2012105588665A patent/CN103319596A/zh active Pending
- 2004-06-15 PL PL04776552T patent/PL1638999T3/pl unknown
- 2004-06-15 BR BRPI0411535-0A patent/BRPI0411535A/pt not_active Application Discontinuation
- 2004-06-15 WO PCT/US2004/018910 patent/WO2005003158A2/en not_active Ceased
- 2004-06-15 ME MEP-31/08A patent/MEP3108A/xx unknown
- 2004-06-15 SG SG2008068264A patent/SG185824A1/en unknown
- 2004-06-15 EP EP10013086A patent/EP2341071A1/en not_active Withdrawn
- 2004-06-15 EA EA200600037A patent/EA014525B1/ru not_active IP Right Cessation
- 2004-06-15 KR KR1020057024173A patent/KR101221147B1/ko not_active Expired - Lifetime
- 2004-06-15 RS YU20050932A patent/RS52769B/sr unknown
- 2004-06-15 ME MEP-2008-31A patent/ME00023B/me unknown
- 2004-06-15 CN CN2004800233260A patent/CN1835968B/zh not_active Expired - Lifetime
- 2004-06-15 EP EP10013087A patent/EP2338906A1/en not_active Ceased
- 2004-06-15 EP EP04776552.4A patent/EP1638999B1/en not_active Expired - Lifetime
2005
- 2005-01-16 NO NO20060235A patent/NO20060235L/no not_active Application Discontinuation
- 2005-12-15 IL IL172599A patent/IL172599A/en active IP Right Grant
2006
- 2006-01-13 ZA ZA200600384A patent/ZA200600384B/xx unknown
- 2006-04-05 US US11/399,210 patent/US7578999B2/en not_active Expired - Lifetime
2009
- 2009-07-16 US US12/504,296 patent/US7985834B2/en not_active Expired - Lifetime
2011
- 2011-07-19 JP JP2011157675A patent/JP2011246482A/ja active Pending
2012
- 2012-10-29 IL IL222756A patent/IL222756A0/en unknown
2013
- 2013-10-09 CY CY20131100883T patent/CY1114701T1/el unknown

Also Published As

Publication number	Publication date
IL172599A0 (en)	2006-04-10
PT1638999E (pt)	2013-09-03
EA201001528A1 (ru)	2011-06-30
KR20060064568A (ko)	2006-06-13
US20060233801A1 (en)	2006-10-19
KR101221147B1 (ko)	2013-01-10
WO2005003158A3 (en)	2005-05-26
US20100151524A1 (en)	2010-06-17
JP2011246482A (ja)	2011-12-08
EP1638999B1 (en)	2013-07-24
EP1638999A2 (en)	2006-03-29
PL1638999T3 (pl)	2014-04-30
RS52769B (sr)	2013-10-31
US7985834B2 (en)	2011-07-26
CY1114701T1 (el)	2016-10-05
CA2529578C (en)	2014-11-18
IL172599A (en)	2016-05-31
BRPI0411535A (pt)	2006-08-01
US7578999B2 (en)	2009-08-25
JP4818107B2 (ja)	2011-11-16
CN1835968A (zh)	2006-09-20
ZA200600384B (en)	2008-10-29
CN103319596A (zh)	2013-09-25
CN1835968B (zh)	2013-01-30
AU2004253870B2 (en)	2011-11-10
CA2529578A1 (en)	2005-01-13
EP2341071A1 (en)	2011-07-06
RS20050932A (sr)	2008-11-28
AU2004253870A1 (en)	2005-01-13
NO20060235L (no)	2006-03-14
WO2005003158A2 (en)	2005-01-13
ES2428767T3 (es)	2013-11-11
HK1088907A1 (en)	2006-11-17
SG185824A1 (en)	2012-12-28
JP2008505843A (ja)	2008-02-28
EA200600037A1 (ru)	2006-06-30
NZ544617A (en)	2009-11-27
EA022991B1 (ru)	2016-04-29
US20040009535A1 (en)	2004-01-15
ME00023B (me)	2010-06-10
DK1638999T3 (da)	2013-10-14
EP2338906A1 (en)	2011-06-29
EA014525B1 (ru)	2010-12-30
IL222756A0 (en)	2012-12-31
SI1638999T1 (sl)	2013-12-31
HRP20131014T1 (hr)	2013-12-20

Publication	Publication Date	Title
MEP3108A (xx)	2010-02-10	Kompozicije i postupci za povećanje mineralizacije kostiju
MEP2808A (xx)	2010-02-10	Antitijela specifična za sklerositin i metode za povećanje mineralizacije kostiju
PH12015501848A1 (en)	2020-07-06	Binding agents
MY174493A (en)	2020-04-23	Binding agents
CY1112797T1 (el)	2016-02-10	Συμπλοκο σκληροστινης και νογκινης ή χορδινης, και παραγοντες που ρυθμιζουν το σχηματισμο του εν λογω συμπλοκου
PH12016501691A1 (en)	2017-07-03	Antibodies to matrix metalloproteinase 9
EA200801621A1 (ru)	2008-12-30	Антитела, направленные на her-3, и их применение
MX2007008017A (es)	2007-09-12	Polipeptidos que se ligan a br3 y usos de los mismos.
WO2005107491A3 (en)	2005-12-22	Multi-lectin affinity chromatography and uses thereof
WO2007098198A3 (en)	2008-03-13	Modulation of bone formation
MY147438A (en)	2012-12-14	Biological materials and uses thereof
EA200801174A1 (ru)	2009-02-27	Антитела-миметики glp-2, полипептиды, композиции, способы и применения
HK1151803B (en)	2015-08-28	Sclerostin binding agents
WO2003046125A3 (en)	2004-07-08	Hin-2 nucleic acid molecules, proteins, antibodies, homologues, receptors, and uses thereof
TW200718711A (en)	2007-05-16	Polypeptides that bind BR3 and uses thereof
WO2006008266A3 (en)	2006-08-03	Factor xi-binding proteins